Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Shares Outstanding (Diluted Average) (2019 - 2025)

10x Genomics (TXG) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $124.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 3.57% to $124.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $124.7 million through Dec 2025, up 3.57% year-over-year, with the annual reading at $124.7 million for FY2025, 3.57% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $124.7 million in Q4 2025 for 10x Genomics, up from $124.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $124.7 million in Q4 2025 to a low of $108.7 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $116.8 million across 5 years, with a median of $116.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 12.27% in 2021 and later rose 2.28% in 2023.
  • Year by year, Shares Outstanding (Diluted Average) stood at $110.3 million in 2021, then increased by 3.18% to $113.9 million in 2022, then increased by 2.9% to $117.2 million in 2023, then rose by 2.81% to $120.5 million in 2024, then grew by 3.57% to $124.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for TXG at $124.7 million in Q4 2025, $124.0 million in Q3 2025, and $124.3 million in Q2 2025.